| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
13,716 |
13,518 |
$717K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
6,944 |
6,907 |
$652K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
14,514 |
14,341 |
$550K |
| 95816 |
|
3,369 |
2,420 |
$438K |
| 99222 |
Initial hospital care, per day, moderate complexity |
2,170 |
2,125 |
$102K |
| 95886 |
|
1,930 |
1,302 |
$87K |
| 95908 |
|
1,676 |
1,142 |
$77K |
| 95909 |
|
1,312 |
880 |
$75K |
| 64615 |
|
738 |
733 |
$63K |
| 95885 |
|
1,045 |
695 |
$28K |
| 99232 |
Subsequent hospital care, per day, moderate complexity |
753 |
461 |
$16K |
| 99070 |
|
2,599 |
2,353 |
$8K |
| 99221 |
|
172 |
170 |
$6K |
| 99442 |
|
202 |
190 |
$3K |
| T1502 |
Administration of oral, intramuscular and/or subcutaneous medication by health care agency/professional, per visit |
45 |
16 |
$3K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
33 |
33 |
$2K |
| 99441 |
|
194 |
170 |
$2K |
| 99205 |
Prolong outpt/office vis |
12 |
12 |
$2K |
| 99443 |
|
57 |
57 |
$1K |
| 64400 |
|
15 |
12 |
$1K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
16 |
16 |
$821.12 |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
14 |
13 |
$466.06 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
30 |
25 |
$385.23 |
| 99231 |
Subsequent hospital care, per day, straightforward or low complexity |
14 |
14 |
$150.33 |
| J0670 |
Injection, mepivacaine hydrochloride, per 10 ml |
210 |
158 |
$14.44 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
46 |
46 |
$0.00 |